Corpus ID: 37174379

Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy.

  title={Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy.},
  author={D. Firat and S. Olshin},
  journal={Cancer chemotherapy reports},
  volume={52 7},
Chemoendocrine therapy in advanced breast cancer
Beneficial effects can be achieved from a combination of these two treatment modalities in human breast cancer when the steroid receptor status and the presence or absence of visceral metastases are considered in the selection of treatment programs. Expand
Comparative activity of ifosfamide and cyclophosphamide
SummaryAntitumor activity (increase in lifespan and cure) was greater for ifosfamide (IFO) in several experimental tumors, some of which were primarily resistant to cyclophosphamide (CYC).IFO hasExpand
A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.
A single-agent dose-response database can be derived from historic literature that enables comparison of the dose-intensity of all combination regimens on one scale and may be useful in guiding dosage increases beyond the conventional range. Expand
Chemosensitivities of human clonogenic breast tumor cells.
It is concluded that the in vitro system provides a valid tool to determine the inherent chemosensitivity pattern of the individual tumor types, and to compare the tumor cytotoxic potential of drugs. Expand
Ifosfamide--current aspects and perspectives.
Hormones by administration
The hormone dependence of human breast cancer was discovered by Beatsonl who reported beneficial effects from oophorectomy as a treatment of this disease and both radiation and surgical castration became established therapeutic procedures in operable or generalised breast cancer. Expand
The chemical therapy of breast cancer.
Within the Division of Cancer Treatment of the National Cancer Institute, the concept of combined modalities is an essential part of the therapeutic strategy aimed at increasing cure rates in all solid tumors. Expand
Corticosteroids in the treatment of solid tumors.
  • M. Brennan
  • Medicine
  • The Medical clinics of North America
  • 1973
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Drug dose, frequency of bony and liver metastases, concomitant irradiation, and previous myelosuppressive therapy did not contribute to this difference; older patients and advanced visceral disease appeared to be the major influencing factors. Expand